COVID-19 drug trials have struggled to recruit volunteers throughout pandemic

COVID-19 vaccines have been developed at a rapid pace that has largely exceeded expectations, and while there are varying levels of success, several appear to be quite effective. The United States government poured a lot of money into the research, which helped push the development finish line up, but the heavy focus on vaccines did leave coronavirus therapeutics behind, The New York Times reports.
A few drug treatments have helped doctors improve the care of COVID-19 patients, but several ideas that looked like they were gaining steam petered out. One of the key factors was a lack of centralized coordination, the Times suggests. Hospitals and researchers have often been left on their own to conduct trials and many have subsequently struggled to find volunteers who were not already hospitalized.
For instance, the University of Kentucky began a trial in May to test a drug called camostat. Normally used to treat inflammation of the pancreas, camostat's ability to destroy a protein the virus depends on to infect human cells had scientists optimistic it could work as a COVID-19 antiviral. But over the past eight months, the research team just hasn't been able to consistently track down patients who recently received a COVID-19 diagnosis.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"This has been the source of delays for essentially all of the trials around the world," Dr. James Porterfield, an infectious disease clinician at the University of Kentucky College of Medicine, told the Times. Read more at The New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
US foodies brace for tariff war
Under The Radar Shoppers stocking up on imported olive oil, maple syrup and European wine as price hikes loom
By Chas Newkey-Burden, The Week UK Published
-
How Canadian tariffs could impact tourism to the US
In the Spotlight Canadians represent the largest group of foreign visitors to the United States. But they may soon stop visiting.
By Justin Klawans, The Week US Published
-
Entitlements: DOGE goes after Social Security
Feature Elon Musk is pushing false claims about Social Security fraud
By The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published